About the company
| 17.81bn | 3.74bn | 1992 | 51.70k | |||
| Revenue in GBP (TTM) | Net income in GBP | Incorporated | Employees |
|---|
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca's products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In August 2012, Alliance Pharma plc's subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands. In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company.
Mergers & acquisitions
| Acquired company | Deal status | Date | AZN:LSE since announced | Transaction value |
|---|---|---|---|---|
| Link Medicine Corp- Neuroscience Assets Portfolio | Deal completed | 12 Jul 2012 | +15.10% | -- |
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excluding extraordinary items (TTM) | EPS (including extraordinary items) (TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on average assets (TTM) | Return on average assets (5 yr average) | Return on investment (TTM) | Return on investment (5 yr average) | Gross margin (TTM) | Gross margin (5 yr average) | Net profit margin (TTM) | Net Profit margin (5 Yr Average) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr average) | Revenue (Year-over-year change%) | Revenue (5 yr growth rate) | Net income (Year-over-year change%) | Net income (5 Yr growth rate) | Capital expenditure (5 Yr growth rate) | Dividend (5 yr growth rate) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire PLC | 3.08bn | 376.95m | 11.43bn | 5367 | 31.29 | 4.66 | 19.68 | 3.71 | 0.6595 | 0.6595 | 5.35 | 4.43 | 0.6532 | 1.53 | 5.14 | 573,786 | 7.99 | 15.07 | 10.17 | 15.07 | 86.15 | 86.40 | 12.23 | 15.54 | 1.77 | 39.47 | 0.2253 | 11.24 | 9.80 | 13.95 | -13.8266 | -- | 2.65 | 12.20 | |
| AstraZeneca plc | 17.81bn | 3.74bn | 42.61bn | 51700 | 11.44 | 2.89 | 6.39 | 2.39 | 2.98 | 2.98 | 14.19 | 11.77 | 0.524 | 2.55 | 3.37 | 344,399 | 11.05 | 20.87 | 15.60 | 20.87 | 80.78 | 81.63 | 21.09 | 23.93 | 1.18 | 21.24 | 0.3122 | 45.01 | -16.7247 | -1.0969 | -36.9228 | 2.39 | 22.43 | 8.41 | |
| GlaxoSmithKline plc | 26.26bn | 4.22bn | 84.36bn | 98681 | 20.27 | 12.39 | 12.96 | 3.21 | 0.845 | 0.845 | 5.30 | 1.38 | 0.6275 | 1.86 | 4.60 | 266,130 | 10.51 | 16.45 | 15.87 | 16.45 | 71.01 | 73.62 | 16.75 | 16.63 | 0.8261 | 12.30 | 0.7172 | 77.44 | -3.4907 | 3.08 | -13.2294 | -2.6236 | -6.6393 | 6.90 | |
| Sanofi SA | 29.74bn | 3.50bn | 95.02bn | 111974 | 26.92 | -- | 15.15 | 3.20 | 3.14 | 3.14 | 26.61 | -- | -- | -- | -- | 314,153 | -- | 6.14 | -- | 6.14 | 68.02 | 70.35 | 11.90 | 13.67 | -- | 14.24 | -- | 64.99 | 2.56 | 4.25 | -12.7525 | -0.5738 | 0.0248 | 6.00 | |
| Novo Nordisk A/S | 9.10bn | 2.58bn | 49.93bn | 35154 | 23.95 | 15.88 | 17.27 | 5.49 | 41.55 | 41.55 | 146.53 | 62.67 | 1.30 | 1.43 | 7.96 | 2,340,839 | 36.80 | 35.54 | 59.84 | 35.54 | 82.97 | 80.69 | 28.35 | 24.30 | 1.02 | -- | 0.0199 | 42.55 | 17.60 | 13.28 | 25.36 | 20.26 | 8.35 | 31.95 |
Data as of May 20 2013. Currency figures normalised to AstraZeneca PLC's reporting currency: .
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
BlackRock Investment Management (UK) Ltd. as of 02 Feb 2012 | 100.89m | 8.07% |
Invesco Asset Management Ltd. as of 02 Feb 2012 | 72.78m | 5.82% |
Legal & General Investment Management Ltd. as of 02 Feb 2012 | 57.68m | 4.62% |
Scottish Widows Investment Partnership Ltd. as of 01 Apr 2013 | 29.26m | 2.37% |
Norges Bank Investment Management as of 01 Apr 2013 | 28.79m | 2.30% |
State Street Global Advisors Ltd. as of 01 Apr 2013 | 14.92m | 1.20% |
Schroder Investment Management Ltd. as of 01 Apr 2013 | 15.54m | 1.18% |
Wellington Management Co. LLP as of 01 Apr 2013 | 14.56m | 1.17% |
State Administration of Foreign Exchange (Invt Mgmt) as of 01 Apr 2013 | 13.76m | 1.10% |
Threadneedle Asset Management Ltd. as of 01 Apr 2013 | 13.66m | 1.09% |
Data from 31 Dec 2012 - 06 May 2013Source: FactSet Research Systems Inc.